Baidu
map

Exp Ther Med:眼眶IgG4相关疾病的临床观察

2019-01-31 MedSci MedSci原创

天津市第一中心医院眼科的Wu N等,在Exp Ther Med杂志上发表了一篇研究论文,研究的目的是观察免疫球蛋白G4相关眼眶疾病(IgG4-RODs)的组织病理学变化,总结眼睑IgG4-RODs的临床表现和影像学特征,探讨IgG4-RODs的早期诊断措施。

天津市第一中心医院眼科的Wu N等,在Exp Ther Med杂志上发表了一篇研究论文,研究的目的是观察免疫球蛋白G4相关眼眶疾病(IgG4-RODs)的组织病理学变化,总结眼睑IgG4-RODs的临床表现和影像学特征,探讨IgG4-RODs的早期诊断措施。

他们在2011年6月至2015年5月期间,招募了天津市第一中心医院眼科的23例非特异性眼眶炎症患者。其中,9名患者血清IgG4的滴度范围为4.58至46.70g / l(参考值,0.03-2.01g / l),平均值为21.93±2.18g / l。值得注意的是,9名IgG4-ROD患者的变化程度不同,但均> 1.35 g / l。同时观察到6例出现眼眶下神经增厚的情况。另外,有3例存在眼外肌增厚症状,1例IgG4-ROD眼眶组织病变的情况是沿下颞隔延伸至左翼腭窝、左骶裂,左上颌窦也受到影响。

该研究表明,下眼眶神经增厚可能是IgG4-ROD的临床特征。因此,作者建议,在临床活检和血清检查的基础上,早期诊断可结合影像学检查、临床表现和实验室检查等,以减少误诊和漏诊。

原文出处:

Wu, N. and F.Y. Sun, Clinical observation of orbital IgG4-related diseases. Exp Ther Med, 2019. 17(1): p. 883-887.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1941608, encodeId=7e53194160875, content=<a href='/topic/show?id=c9752300260' target=_blank style='color:#2F92EE;'>#临床观察#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23002, encryptionId=c9752300260, topicName=临床观察)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Wed Dec 18 08:19:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482969, encodeId=0ef3148296982, content=<a href='/topic/show?id=5d52950839' target=_blank style='color:#2F92EE;'>#IgG4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9508, encryptionId=5d52950839, topicName=IgG4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcbb7863836, createdName=ms5106640509429053, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583968, encodeId=60e515839687c, content=<a href='/topic/show?id=3b02e2794f3' target=_blank style='color:#2F92EE;'>#眼眶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72794, encryptionId=3b02e2794f3, topicName=眼眶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598945, encodeId=cf9a159894553, content=<a href='/topic/show?id=2de3951465' target=_blank style='color:#2F92EE;'>#IgG4相关疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9514, encryptionId=2de3951465, topicName=IgG4相关疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43c618641271, createdName=jiekemin, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609522, encodeId=c689160952210, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615196, encodeId=3ab416151969a, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359752, encodeId=cf30359e52e2, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Fri Feb 01 19:16:25 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359666, encodeId=0ae035966628, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Thu Jan 31 14:26:20 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1941608, encodeId=7e53194160875, content=<a href='/topic/show?id=c9752300260' target=_blank style='color:#2F92EE;'>#临床观察#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23002, encryptionId=c9752300260, topicName=临床观察)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Wed Dec 18 08:19:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482969, encodeId=0ef3148296982, content=<a href='/topic/show?id=5d52950839' target=_blank style='color:#2F92EE;'>#IgG4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9508, encryptionId=5d52950839, topicName=IgG4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcbb7863836, createdName=ms5106640509429053, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583968, encodeId=60e515839687c, content=<a href='/topic/show?id=3b02e2794f3' target=_blank style='color:#2F92EE;'>#眼眶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72794, encryptionId=3b02e2794f3, topicName=眼眶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598945, encodeId=cf9a159894553, content=<a href='/topic/show?id=2de3951465' target=_blank style='color:#2F92EE;'>#IgG4相关疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9514, encryptionId=2de3951465, topicName=IgG4相关疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43c618641271, createdName=jiekemin, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609522, encodeId=c689160952210, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615196, encodeId=3ab416151969a, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359752, encodeId=cf30359e52e2, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Fri Feb 01 19:16:25 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359666, encodeId=0ae035966628, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Thu Jan 31 14:26:20 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1941608, encodeId=7e53194160875, content=<a href='/topic/show?id=c9752300260' target=_blank style='color:#2F92EE;'>#临床观察#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23002, encryptionId=c9752300260, topicName=临床观察)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Wed Dec 18 08:19:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482969, encodeId=0ef3148296982, content=<a href='/topic/show?id=5d52950839' target=_blank style='color:#2F92EE;'>#IgG4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9508, encryptionId=5d52950839, topicName=IgG4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcbb7863836, createdName=ms5106640509429053, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583968, encodeId=60e515839687c, content=<a href='/topic/show?id=3b02e2794f3' target=_blank style='color:#2F92EE;'>#眼眶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72794, encryptionId=3b02e2794f3, topicName=眼眶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598945, encodeId=cf9a159894553, content=<a href='/topic/show?id=2de3951465' target=_blank style='color:#2F92EE;'>#IgG4相关疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9514, encryptionId=2de3951465, topicName=IgG4相关疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43c618641271, createdName=jiekemin, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609522, encodeId=c689160952210, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615196, encodeId=3ab416151969a, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359752, encodeId=cf30359e52e2, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Fri Feb 01 19:16:25 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359666, encodeId=0ae035966628, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Thu Jan 31 14:26:20 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1941608, encodeId=7e53194160875, content=<a href='/topic/show?id=c9752300260' target=_blank style='color:#2F92EE;'>#临床观察#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23002, encryptionId=c9752300260, topicName=临床观察)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Wed Dec 18 08:19:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482969, encodeId=0ef3148296982, content=<a href='/topic/show?id=5d52950839' target=_blank style='color:#2F92EE;'>#IgG4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9508, encryptionId=5d52950839, topicName=IgG4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcbb7863836, createdName=ms5106640509429053, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583968, encodeId=60e515839687c, content=<a href='/topic/show?id=3b02e2794f3' target=_blank style='color:#2F92EE;'>#眼眶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72794, encryptionId=3b02e2794f3, topicName=眼眶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598945, encodeId=cf9a159894553, content=<a href='/topic/show?id=2de3951465' target=_blank style='color:#2F92EE;'>#IgG4相关疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9514, encryptionId=2de3951465, topicName=IgG4相关疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43c618641271, createdName=jiekemin, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609522, encodeId=c689160952210, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615196, encodeId=3ab416151969a, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359752, encodeId=cf30359e52e2, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Fri Feb 01 19:16:25 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359666, encodeId=0ae035966628, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Thu Jan 31 14:26:20 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1941608, encodeId=7e53194160875, content=<a href='/topic/show?id=c9752300260' target=_blank style='color:#2F92EE;'>#临床观察#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23002, encryptionId=c9752300260, topicName=临床观察)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Wed Dec 18 08:19:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482969, encodeId=0ef3148296982, content=<a href='/topic/show?id=5d52950839' target=_blank style='color:#2F92EE;'>#IgG4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9508, encryptionId=5d52950839, topicName=IgG4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcbb7863836, createdName=ms5106640509429053, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583968, encodeId=60e515839687c, content=<a href='/topic/show?id=3b02e2794f3' target=_blank style='color:#2F92EE;'>#眼眶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72794, encryptionId=3b02e2794f3, topicName=眼眶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598945, encodeId=cf9a159894553, content=<a href='/topic/show?id=2de3951465' target=_blank style='color:#2F92EE;'>#IgG4相关疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9514, encryptionId=2de3951465, topicName=IgG4相关疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43c618641271, createdName=jiekemin, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609522, encodeId=c689160952210, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615196, encodeId=3ab416151969a, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359752, encodeId=cf30359e52e2, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Fri Feb 01 19:16:25 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359666, encodeId=0ae035966628, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Thu Jan 31 14:26:20 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1941608, encodeId=7e53194160875, content=<a href='/topic/show?id=c9752300260' target=_blank style='color:#2F92EE;'>#临床观察#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23002, encryptionId=c9752300260, topicName=临床观察)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Wed Dec 18 08:19:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482969, encodeId=0ef3148296982, content=<a href='/topic/show?id=5d52950839' target=_blank style='color:#2F92EE;'>#IgG4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9508, encryptionId=5d52950839, topicName=IgG4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcbb7863836, createdName=ms5106640509429053, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583968, encodeId=60e515839687c, content=<a href='/topic/show?id=3b02e2794f3' target=_blank style='color:#2F92EE;'>#眼眶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72794, encryptionId=3b02e2794f3, topicName=眼眶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598945, encodeId=cf9a159894553, content=<a href='/topic/show?id=2de3951465' target=_blank style='color:#2F92EE;'>#IgG4相关疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9514, encryptionId=2de3951465, topicName=IgG4相关疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43c618641271, createdName=jiekemin, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609522, encodeId=c689160952210, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615196, encodeId=3ab416151969a, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359752, encodeId=cf30359e52e2, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Fri Feb 01 19:16:25 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359666, encodeId=0ae035966628, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Thu Jan 31 14:26:20 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1941608, encodeId=7e53194160875, content=<a href='/topic/show?id=c9752300260' target=_blank style='color:#2F92EE;'>#临床观察#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23002, encryptionId=c9752300260, topicName=临床观察)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Wed Dec 18 08:19:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482969, encodeId=0ef3148296982, content=<a href='/topic/show?id=5d52950839' target=_blank style='color:#2F92EE;'>#IgG4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9508, encryptionId=5d52950839, topicName=IgG4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcbb7863836, createdName=ms5106640509429053, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583968, encodeId=60e515839687c, content=<a href='/topic/show?id=3b02e2794f3' target=_blank style='color:#2F92EE;'>#眼眶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72794, encryptionId=3b02e2794f3, topicName=眼眶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598945, encodeId=cf9a159894553, content=<a href='/topic/show?id=2de3951465' target=_blank style='color:#2F92EE;'>#IgG4相关疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9514, encryptionId=2de3951465, topicName=IgG4相关疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43c618641271, createdName=jiekemin, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609522, encodeId=c689160952210, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615196, encodeId=3ab416151969a, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359752, encodeId=cf30359e52e2, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Fri Feb 01 19:16:25 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359666, encodeId=0ae035966628, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Thu Jan 31 14:26:20 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
    2019-02-01 orangesking

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1941608, encodeId=7e53194160875, content=<a href='/topic/show?id=c9752300260' target=_blank style='color:#2F92EE;'>#临床观察#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23002, encryptionId=c9752300260, topicName=临床观察)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Wed Dec 18 08:19:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482969, encodeId=0ef3148296982, content=<a href='/topic/show?id=5d52950839' target=_blank style='color:#2F92EE;'>#IgG4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9508, encryptionId=5d52950839, topicName=IgG4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcbb7863836, createdName=ms5106640509429053, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583968, encodeId=60e515839687c, content=<a href='/topic/show?id=3b02e2794f3' target=_blank style='color:#2F92EE;'>#眼眶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72794, encryptionId=3b02e2794f3, topicName=眼眶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598945, encodeId=cf9a159894553, content=<a href='/topic/show?id=2de3951465' target=_blank style='color:#2F92EE;'>#IgG4相关疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9514, encryptionId=2de3951465, topicName=IgG4相关疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43c618641271, createdName=jiekemin, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609522, encodeId=c689160952210, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615196, encodeId=3ab416151969a, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Sat Feb 02 04:19:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359752, encodeId=cf30359e52e2, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Fri Feb 01 19:16:25 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359666, encodeId=0ae035966628, content=学习了,涨知识了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Thu Jan 31 14:26:20 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
    2019-01-31 王秀

    学习了,涨知识了!

    0

相关资讯

Ophthalmic Plast Reconstr Surg:人体眼眶的胚胎学和发育综述

埃及开罗艾因夏姆斯大学眼科的Tawfik HA和北卡罗来纳大学医学院眼科的Dutton JJ等近日在Ophthalmic Plast Reconstr Surg杂志上发表了一篇文章,他们回顾了最近关于眼眶研究进展的数据,对从胚胎生命早期阶段到胎儿晚期成熟过程中出现的争议等进行了讨论,并对眼眶中特定结构的形态发生进行综述。

Acta Clin Croat:彩色多普勒超声检测早期甲状腺功能亢进视神经病变的眼眶血管的血流变化

克罗地亚斯普利特大学医院中心眼科的LesinM等人近日在Acta Clin Croat上发表了一项重要工作。甲状腺相关眼眶病(TAO)是一种格雷夫斯病的常见表现。在TAO中约有6%的患者会发展为甲状腺功能亢进性视神经病变(DON),而这是TAO最严重的并发症。该研究的目的就是研究其发生过程。

Ophthalmic Plast Reconstr Surg:使用尼龙箔植入物进行眼眶顶重建

加州大学欧文分校加文赫伯特眼科研究所的Grob SR等人近日在Ophthalmic Plast Reconstr Surg杂志上发表了一篇重要的文章,他们在论文中描述了使用薄尼龙箔植入物对眶顶进行重建的外科技术方法。

CT诊断眶内木质异物1例

患者男性,37岁。

Ophthalmic Plast Reconstr Surg:侵入眼眶的结膜性假腺瘤增生

纽约大学Langone医学中心眼科和病理学系的Charles NC近日在Ophthalmic Plast Reconstr Surg发表一篇病例报告,他们在一例患者中发现侵入眼眶的结膜性假腺瘤增生。

Ophthalmic Plast Reconstr Surg:可吸收植入异物可以引起眼眶组织炎症

美国密歇根大学医学院眼科学与视觉科学系的Shaughness GJ等人近日在Ophthalmic Plast Reconstr Surg上发表了研究论文,作者描述了一名7岁男孩的病例,该男孩使用聚DL-丙交酯聚合物来修复眼睛爆裂性骨折,植入10个月后出现眼眶炎症。

Baidu
map
Baidu
map
Baidu
map